Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,025 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: high dose +Placebo Clear all
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Examine the Acute Impact of Veillonella Supplementation on Exercise and Lactate Responses

NCT05816291
View directory record Official record
Conditions
Lactate Blood Increase, Exhaustion - Physiological
Interventions
Time to Exhaustion at velocity at VO2max
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 4, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 4, 2026, 3:59 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

NCT07628049
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Lenexa, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
70
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Digitoxin to Treat Cystic Fibrosis

NCT00782288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
digitoxin, placebo
Drug · Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

An Acupuncture Functional Magnetic Resonance Imaging (fMRI) Study on Chronic Pain: Response Reliability and Dose Effect

NCT01079390
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
acupuncture
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 4, 2026, 3:59 AM EDT
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Dose-Ranging Study in Women

NCT01960686
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 4, 2026, 3:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Supplementation on Gastrointestinal Barrier Function

NCT06262880
View directory record Official record
Conditions
Intestinal Permeability
Interventions
plant derived phenolics, Microcrystaline cellulose (MCC)
Dietary Supplement · Other
Lead sponsor
Brightseed
Industry
Eligibility
30 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

NCT06716879
View directory record Official record
Conditions
Healthy Participants
Interventions
Donzakimig, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

NCT02951182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ, IVA, VX-440, Matched Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 4, 2026, 3:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Study of ST-100 as Treatment for Dry Eye Disease

NCT05241470
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Stuart Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

NCT01966666
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

NCT07102459
View directory record Official record
Conditions
Acute Pain, Postoperative Pain Control
Interventions
Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator
Drug
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT02267382
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
VT-1161, Placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCT02876900
View directory record Official record
Conditions
Schizophrenia
Interventions
Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 4, 2026, 3:59 AM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

NCT02603081
View directory record Official record
Conditions
Meniere's Disease
Interventions
SPI-1005
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

Safety Study of Chinese Herbal Therapy to Treat Asthma

NCT00601263
View directory record Official record
Conditions
Asthma
Interventions
Anti-Asthma Herbal Medical Intervention (ASHMI)
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 4, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children

NCT01652287
View directory record Official record
Conditions
Children
Interventions
BB-12 supplemented strawberry yogurt, Strawberry flavored yogurt
Drug · Other
Lead sponsor
Georgetown University
Other
Eligibility
1 Year to 5 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 4, 2026, 3:59 AM EDT